Protagonist Therapeutics Inc
NASDAQ:PTGX

Watchlist Manager
Protagonist Therapeutics Inc Logo
Protagonist Therapeutics Inc
NASDAQ:PTGX
Watchlist
Price: 92.25 USD 0.95% Market Closed
Market Cap: 5.8B USD

Wall Street
Price Targets

PTGX Price Targets Summary
Protagonist Therapeutics Inc

Wall Street analysts forecast PTGX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PTGX is 92.53 USD with a low forecast of 65.65 USD and a high forecast of 117.6 USD.

Lowest
Price Target
65.65 USD
29% Downside
Average
Price Target
92.53 USD
0% Upside
Highest
Price Target
117.6 USD
27% Upside
Protagonist Therapeutics Inc Competitors:
Price Targets
BVXP
Bioventix PLC
131% Upside
VOR
Vor Biopharma Inc
236% Upside
ADCT
ADC Therapeutics SA
95% Upside
CHRS
Coherus BioSciences Inc
257% Upside
DSGN
Design Therapeutics Inc
30% Upside
CRSP
CRISPR Therapeutics AG
38% Upside
CRNX
Crinetics Pharmaceuticals Inc
66% Upside
HOWL
Werewolf Therapeutics Inc
477% Upside

Revenue
Forecast

Revenue Estimate
Protagonist Therapeutics Inc

The compound annual growth rate of Protagonist Therapeutics Inc's revenue for the next 3 years is -25%.

N/A
Past Growth
-25%
Estimated Growth
Estimates Accuracy
11%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Protagonist Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Net Income
Forecast

Net Income Estimate
Protagonist Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-47%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PTGX's stock price target?
Price Target
92.53 USD

According to Wall Street analysts, the average 1-year price target for PTGX is 92.53 USD with a low forecast of 65.65 USD and a high forecast of 117.6 USD.

What is Protagonist Therapeutics Inc's Revenue forecast?
Projected CAGR
-25%

The compound annual growth rate of Protagonist Therapeutics Inc's revenue for the next 3 years is -25%.

Back to Top